Chiusolo, P., Salutari, P., Sica, S., Scirpa, P., Laurenti, L., Piccirillo, N., & Leone, G. (1998). Luteinizing hormone-releasing hormone analogue: Leuprorelin acetate for the prevention of menstrual bleeding in premenopausal women undergoing stem cell transplantation. Bone Marrow Transplantation, 21, 821–823.
Low-dose leuprorelin acetate (Lupron®) 3.75 mg given subcutaneously at least 30 days prior to transplant conditioning regimen and the second injection given 28 days after the first
Mean duration of thrombocytopenia was 28 days; only one patient developed menstrual bleeding during this time. No side effects related to leuprorelin acetate were noted.